Peripheral Interventions - Global Strategic Business Report

The global market for Peripheral Interventions was valued at US$10.8 Billion in 2024 and is projected to reach US$16.3 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Peripheral Interventions market.

Global Peripheral Interventions Market - Key Trends & Drivers Summarized

Why Are Peripheral Interventions Gaining Traction in Modern Vascular Therapy?

Peripheral interventions-minimally invasive procedures that treat blockages or abnormalities in blood vessels outside the heart and brain-are becoming an integral part of vascular care as chronic vascular diseases escalate globally. These interventions encompass procedures such as angioplasty, stenting, atherectomy, thrombectomy, embolization, and endovenous ablation. They are employed to manage peripheral artery disease (PAD), deep vein thrombosis (DVT), varicose veins, aneurysms, and arteriovenous malformations.

The surge in PAD cases, attributed to aging populations, diabetes, smoking, and sedentary lifestyles, is fueling demand for catheter-based revascularization techniques that avoid the complications and recovery times associated with open vascular surgery. Endovascular therapy allows for vessel dilation, plaque removal, or clot extraction using low-profile devices guided via femoral, radial, or pedal access. As awareness about early-stage vascular disease improves, more patients are being treated proactively using peripheral intervention before the onset of critical limb ischemia (CLI) or tissue loss.

Non-atherosclerotic vascular conditions such as venous reflux disease, pelvic congestion syndrome, and dialysis access dysfunction are also being increasingly managed using peripheral techniques. The growth of hybrid vascular ORs, outpatient-based labs (OBLs), and interventional radiology suites is enabling greater procedural access and same-day discharge pathways. The shift toward value-based vascular care models is reinforcing the importance of less invasive, cost-effective, and outcome-optimized interventional therapies.

How Are Device Innovations and Imaging Technologies Redefining Outcomes?

Device miniaturization, improved guidewire technology, and enhanced catheter maneuverability have revolutionized peripheral interventions. Drug-coated balloons (DCBs) and drug-eluting stents (DES) have reduced restenosis rates in femoropopliteal and infrapopliteal segments. Atherectomy devices-rotational, orbital, laser, or directional-are being tailored to specific lesion morphologies and calcification patterns, improving plaque debulking and vessel preparation in complex PAD.

Ultrasound and intravascular imaging modalities such as IVUS (intravascular ultrasound) and OCT (optical coherence tomography) are now being deployed to assess lesion characteristics, guide device sizing, and evaluate post-procedural outcomes in real-time. 3D vascular navigation and robotic catheters are also being tested for enhanced procedural control and reproducibility. Embolic protection devices and vessel closure systems are increasing safety margins in high-risk procedures.

In venous interventions, laser and radiofrequency ablation catheters are replacing surgical stripping for varicose vein treatment, providing faster recovery and reduced recurrence. For DVT and pulmonary embolism, mechanical thrombectomy systems like aspiration catheters and rotating baskets are allowing for clot removal without systemic thrombolytics, reducing bleeding risks. Innovations in scaffold materials, biodegradable stents, and sheathless systems are also expanding the anatomical reach and durability of peripheral therapies.

Which Clinical Segments and Regional Markets Are Leading Peripheral Interventional Growth?

Peripheral interventions span a wide range of specialties including interventional cardiology, interventional radiology, vascular surgery, and nephrology. The most significant clinical growth is occurring in PAD management, especially in below-the-knee (BTK) interventions for patients with diabetes or renal disease. Revascularization of long, calcified lesions and treatment of chronic total occlusions (CTOs) are becoming more feasible with specialty crossing devices and low-profile balloons.

The dialysis access segment is another growing niche, where arteriovenous fistula (AVF) stenoses are treated using balloon angioplasty, stent grafts, or thrombectomy to restore flow and preserve access longevity. Endovenous interventions for venous reflux, pelvic venous insufficiency, and post-thrombotic syndrome are also expanding with new embolization coils, adhesives, and sclerosants. Uterine fibroid embolization and prostate artery embolization represent non-oncologic, minimally invasive alternatives to surgery in the reproductive health domain.

Geographically, North America dominates due to high procedural volumes, robust interventional infrastructure, and wide reimbursement coverage. Europe is focused on personalized vascular care pathways and adoption of DCBs and atherectomy systems. Asia-Pacific, particularly China and India, is seeing explosive growth due to rising vascular disease burden, increasing cath lab penetration, and expanding interventional training. Middle Eastern and Latin American markets are gradually adopting peripheral interventions through public-private healthcare investments.

What Is Driving Growth in the Global Peripheral Interventions Market?

The growth in the global peripheral interventions market is driven by the rising prevalence of peripheral vascular disease, rapid technology innovation, increasing adoption of minimally invasive therapies, and the global shift toward outpatient and preventive vascular care. As the burden of chronic vascular conditions rises, particularly in aging and diabetic populations, peripheral interventions offer an effective and efficient treatment paradigm.

Regulatory approvals for newer-generation DCBs, stent platforms, and embolic agents are accelerating procedural adoption. Meanwhile, supportive reimbursement policies, integration of endovascular procedures in outpatient centers, and enhanced cross-specialty training are expanding procedural reach and acceptance. Patient preference for non-surgical interventions, combined with improved long-term outcomes and lower complication risks, further strengthens market momentum.

As vascular care evolves into a data-driven, outcome-focused specialty, peripheral interventions will remain a cornerstone of therapy. The market is poised for continued expansion as healthcare systems prioritize limb preservation, cardiovascular risk reduction, and minimally invasive disease management strategies.

Scope of the Report

The report analyzes the Peripheral Interventions market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:

• Segments: Intervention Type (Atherectomy Intervention, Stent Implantation Intervention, Angioplasty Intervention, Thrombectomy Intervention, Embolization Intervention); Device Type (Interventional Catheters, Interventional Stents, Guide Wires, Interventional Balloons, Embolic Coils); Indication (Coronary Artery Disease Indication, Stroke Indication, Peripheral Arterial Disease Indication, Renal Artery Stenosis Indication, Carotid Artery Stenosis Indication); End-User (Hospitals End-User, Ambulatory Surgery Centers End-User, Clinics End-User, Research Institutes End-User).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Atherectomy Intervention segment, which is expected to reach US$6.5 Billion by 2030 with a CAGR of a 5.7%. The Stent Implantation Intervention segment is also set to grow at 7.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.9 Billion in 2024, and China, forecasted to grow at an impressive 10.9% CAGR to reach $3.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Peripheral Interventions Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Peripheral Interventions Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Peripheral Interventions Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories (Abbott Vascular), Bayer AG, Biotronik SE & Co KG, Boston Scientific Corp., Cardinal Health and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Peripheral Interventions market report include:

• Abbott Laboratories (Abbott Vascular)
• Bayer AG
• Biotronik SE & Co KG
• Boston Scientific Corp.
• Cardinal Health
• Cook Medical
• Cordis (Johnson & Johnson)
• Edward Lifesciences
• Getinge AB
• Inari Medical
• Johnson & Johnson (Cordis, Biosense)
• LeMaitre Vascular
• Medtronic plc
• Merit Medical Systems
• NuVasive (spine but vascular tools)
• Penumbra Inc.
• Philips (Royal Philips)
• Reflow Medical
• Siemens Healthineers
• Stryker (Inari acquisition)

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025 (E), competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.